Another R&D Deal For Takeda As It Inks Parkinson’s Alliance

Deals and R&D partnerships are coming thick and fast for Takeda in the first few days of the year, with the major Japanese firm unveiling a new tie-up with NsGene to progress direct-delivered cell therapies for Parkinson's disease.

TOKYO - Takeda Pharmaceutical Co. Ltd. has entered into a basic research collaboration with NsGene AS for the development of an encapsulated cell therapy for Parkinson's disease, which will focus on the delivery of a neuro-regenerative growth factor to areas of the brain affected by the degenerative disorder.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Japan

More from Focus On Asia